Comparing Sigyn Therapeutics (OTCMKTS:SIGY) and Quipt Home Medical (NASDAQ:QIPT)

Quipt Home Medical (NASDAQ:QIPT) and Sigyn Therapeutics (OTCMKTS:SIGY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility & Risk

Quipt Home Medical has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Sigyn Therapeutics has a beta of -1.68, indicating that its stock price is 268% less volatile than the S&P 500.

Insider and Institutional Ownership

42.9% of Quipt Home Medical shares are held by institutional investors. Comparatively, 10.0% of Sigyn Therapeutics shares are held by institutional investors. 4.2% of Quipt Home Medical shares are held by insiders. Comparatively, 78.5% of Sigyn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Quipt Home Medical and Sigyn Therapeutics’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quipt Home Medical	$221.74 million	0.74	-$2.78 million	($0.09)	-42.77
Sigyn Therapeutics	N/A	N/A	-$4.15 million	($3.60)	-1.60

Quipt Home Medical has higher revenue and earnings than Sigyn Therapeutics. Quipt Home Medical is trading at a lower price-to-earnings ratio than Sigyn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quipt Home Medical and Sigyn Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quipt Home Medical	-1.50%	-3.57%	-1.54%
Sigyn Therapeutics	N/A	N/A	-958.06%

Analyst Recommendations

This is a breakdown of recent recommendations for Quipt Home Medical and Sigyn Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quipt Home Medical	0	1	1	0	2.50
Sigyn Therapeutics	0	0	0	0	N/A

Quipt Home Medical currently has a consensus target price of $10.00, suggesting a potential upside of 159.74%. Given Quipt Home Medical’s higher possible upside, equities analysts clearly believe Quipt Home Medical is more favorable than Sigyn Therapeutics.

Summary

Quipt Home Medical beats Sigyn Therapeutics on 8 of the 12 factors compared between the two stocks.

About Quipt Home Medical

Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.